Search Results

You are looking at 1 - 10 of 34 items for :

  • "erythropoiesis stimulating agents" x
Clear All
Full access

John A. Glaspy

. Cancer Lett 2004 ; 214 : 243 – 251 . 75. Sinclair AM Todd MD Forsythe K . Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients . Cancer 2007 ; 110

Full access

Jeffrey Crawford and George M. Rodgers

Iron for Cancer-Related Anemia Dr. Rodgers discussed the use of IV iron to optimize erythropoietic growth factor therapy or to minimize the need for it. Cancer-related anemia can be treated with erythropoiesis-stimulating agents (ESAs), red blood cell

Full access

John Glaspy

hepcidin, is frequently present in patients with cancer. Abbreviations: eEPO, endogenous erythropoietin; ESA, erythropoiesis-stimulating agent; IFN, interferon; IL, interleukin; RE, reticuloendothelial; TNF, tumor necrosis factor. From Glaspy JA

Full access

George M. Rodgers

Cancer- and Chemotherapy-Induced Anemia during its early years and have chaired it since 2004. Major changes in the NCCN Guidelines on anemia over the years have focused on 2 topics: erythropoiesis-stimulating agent (ESA) safety and the increasing use of

Full access

Rafael Bejar

Myelodysplastic Syndromes. Version 2.209. To view the most recent version, visit . Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; ESAs, erythropoiesis-stimulating agents. For patients without del(5q) deletion, however

Full access

Jennifer M. Hinkel, Edward C. Li and Stephen L. Sherman

, pharmacy, and clinical resources than other patients with cancer. Over the past several years, new paradigms have emerged for the treatment of cancer- and chemotherapy-induced anemia, specifically in the context of using erythropoiesis stimulating agents

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

iron overload in the treatment of patients with myelodysplastic syndromes . Cancer 2008 ; 112 : 1089 – 1095 . 20 Vekeman F Bookhart BK White J . Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on

Full access

Andrew D. Zelenetz, Islah Ahmed, Edward Louis Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richard Markus, Ursula A. Matulonis, Denise Reinke, Edward C. Li, Jessica DeMartino, Jonathan K. Larsen and James M. Hoffman

, with varying requirements for clinical trials. Seven biosimilar molecules have been approved under 14 different marketing applications in Europe, whereas 5 products were withdrawn or rejected by the EMA. Biosimilar erythropoiesis-stimulating agents (ESA

Full access

Mikkael A. Sekeres

watchful waiting, erythropoiesis stimulating agents (ESAs), or lenalidomide, whereas higher-risk patients, in whom these drugs have limited efficacy, should be treated with hypomethylating agents or hematopoietic stem cell transplantation. 49 , 50

Full access

Anat Gafter-Gvili, David P. Steensma and Michael Auerbach

More than a decade has passed since Auerbach et al 1 presented the first study demonstrating synergy of intravenous (IV) iron with erythropoiesis-stimulating agents (ESAs) for correcting anemia in patients receiving chemotherapy for malignant